mai President Prapan Charoenprawatt said IP would list and start trading on mai in Consumer Products industry group.
IP distributes, develops and researches human healthcare and aesthetic innovation products, including companion and farm animal health products. The product lines cover wellness and anti-aging products, aesthetic innovation products, companion animal health products and livestock products. The company's proprietary products are produced by domestic and overseas factories under its own brand such as Probac 7 and Probac 10. The company's own products contribute approximately 40 percent to the total sales, while products supplied by other pharmaceutical companies contribute 60 percent.
IP has a registered paid-up capital of THB 103 million, consisting of 160 million existing common shares and 46 million newly issued shares, with a par value of THB 0.50 each. It offered the entire newly issued shares to general public via IPO at THB 7 each for a total of THB 322 million during October 28-30. Advisory Plus Co., Ltd. is its financial advisor and KTB Securities (Thailand) pcl serves as its lead underwriter.
IP Chief Executive Officer Songwut Sakchalathorn said the company aims at becoming a leader in research and development of effective healthcare products with safety in preventing and curing; prioritizing in health, wellness and anti-aging products, catering to the growing health conscious and aging society. The fund raised will be used for debt repayment and as working capital.
After the IPO, IP's largest shareholder is Mr.Songwut Sakchalathorn (51.12 percent). The IPO price was equivalent to price-to-earnings (P/E) ratio of 53.85 times, calculated by using the company's net profit in the past 12 months (July 1, 2018 - June 30, 2019) amounting to THB 26.66 million, divided by fully diluted shares, representing earnings per share of THB 0.13.The company's dividend policy is to pay no less than 50 percent of net profit of the company's separate financial statement after legal reserves.
For more information on IP, please see the company's prospectus at the Securities and Exchange Commission's website at www.sec.or.th ; and for general information, please visit www.interpharma.co.th and www.set.or.th.